Both surgical and percutaneous RVAD provided immediate improvement in hemodynamic profiles for patients. While surgical RVAD provided higher overall flow than percutaneous the hemodynamic improvements were similar between these two types of device. Finally, percutaneous RVAD use was associated with less morbidity than surgical devices. 
INTRODUCTION
Early right ventricular (RV) failure affects up to 30-40% of patients undergoing left ventricular assist device (LVAD) insertion, and is associated with increased morbidity and mortality in this population. [1] [2] [3] [4] [5] Multiple tools for identifying patients at risk of RV failure have been proposed with varying degrees of accuracy. [2] [3] [4] 6 While some patients are supported sufficiently with medical therapy, others require RV mechanical support, traditionally with surgically implanted devices.
Since early RV dysfunction often improves sufficiently over a short period of time, many patients may not require prolonged RV mechanical support. 7 Typically, recovery occurs within days to weeks, making temporary mechanical support with less invasive modalities an attractive alternative to surgically placed devices in this population as a bridge to recovery.
As an alternative to surgical right ventricular assist device (sRVAD), recent advances in percutaneous technology have brought multiple devices into practice that allow rapid deployment of RV mechanical support percutaneously. [7] [8] [9] [10] [11] These devices include the Impella RP (Abiomed, Danvers, MA), a micro-axial flow intra-corporeal device, and the Protek Duo (TandemLife, Pittsburgh, PA) dual lumen cannula which can be used with a centrifugal flow extra-corporeal pump.
Currently, data regarding the efficacy of support with such percutaneous devices are limited. In the present study, we sought to characterize the hemodynamic effects and outcomes observed with percutaneous RVADs (pRVAD) and compare them to those associated with sRVADs.
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METHODS
Patient Population
We retrospectively reviewed all patients who underwent isolated pRVAD or sRVAD implantation at Columbia University after durable LVAD insertion between acute myocardial infarction, post-cardiotomy shock), or those who had any RVAD implanted concomitantly with the LVAD were excluded from the analysis. Two patients who received both pRVAD and sRVAD were excluded from the analysis (one received sRVAD first, one received pRVAD first). This study was approved by the Columbia University Institutional Review Board.
Variables and Outcomes of Interest
All clinical data were collected through a review of electronic medical records.
Demographic and clinical information were collected including comorbidities and laboratory values. Hemodynamic data including LVAD flows were collected prior to RVAD insertion, 12 and 24 hours after device insertion, and 24 hours following device Hemodynamics measured after durable LVAD implantation at the time of RVAD implantation were similar between the two groups and reflect a population with significant hemodynamic compromise ( Table 2 ). Prior to RVAD implantation, patients in the combined cohort had a mean CVP of 15.9 ± 2.8 mmHg with diastolic pulmonary Indicators of end organ function were similar with pRVAD and sRVAD support, with similar serum lactate levels, creatinine, and urine output between the two groups (Table 3) . Serum lactate was reduced 24 hours after pRVAD insertion, though this difference was not statistically significant (2.28 ± 1.4 vs. 1.60 ± 1.53mg/dL, p=0.13).
There was no significant change in renal function with pRVAD support as measured by serum creatinine (1.63 ± 0.6 vs. 1.78 ± 1.0 mg/dL, p=0.56), though there was a trend
towards an increase in urine output (1700 ± 1145 vs. 3081 ± 3017 mL/24hr, p=0.07) at 48 hours ( Figure 4C ).
Patients who received pRVAD had a median time on the device of 9 days (IQR 
DISCUSSION
Our data provide a comparison between sRVAD and two more recent percutaneous options for RVAD support following durable LVAD implantation. Our ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T principal findings are as follows: 1) both sRVAD and pRVAD support systems provided immediate improvement in hemodynamic profiles for patients, 2) while sRVAD provided higher overall flow than pRVAD the hemodynamic improvements were similar between these two types of device, and 3) pRVAD use was associated with less morbidity than sRVAD use. Our goal was not to compare the two percutaneous devices studied here, but rather to compare the percutaneous approach to the more traditional surgical intervention.
In our cohort of patients with severe RV failure after LVAD implantation, pRVAD and sRVAD support both provided immediate improvement in hemodynamic parameters. Despite pRVAD support resulting in lower flow compared to sRVAD support, hemodynamics were comparable with the two devices. Specifically, we observed a significant reduction in CVP and improvement in cardiac output as well as an improvement in MAP with rapid decrease in vasopressor dose requirement seen within hours of pRVAD placement. Not surprisingly, this was coupled with a doubling of the daily urine output, though this was not statistically significant (p=0.07).
Importantly, in the majority of patients, the RV was able to recover from the various insults experienced in the post-operative period so that the device could be removed. While the mean SVR was within normal limits for the study cohort, it is important to understand that this was while patients were receiving multiple vasopressors at high doses. This underscores the fact that the typical hemodynamic profile of RV failure after LVAD implantation is one of a vasoplegic patient with a relatively low cardiac index (despite LVAD and multiple inotropes). While the RV will typically be able to eventually wean from support, when faced with vasodilatory
A C C E P T E D M A N U S C R I P T
physiology it is unable to provide that increase in cardiac output that would compensate for the reduction in SVR. In combination, these two hemodynamic derangements can be very hard to overcome with vasoactive medications alone. For this reason, easily deployed circulatory support devices designed to support the RV and spare the patient's end-organs from the effects of high dose vasoconstrictors have the potential to significantly improve the recovery from LVAD implantation for those who transiently manifest this pathophysiology.
Several authors have previously described the use of percutaneous or minimally invasive RVADs. Kapur et al. reported the first study using percutaneous mechanical RV support with the TandemHeart device in 9 patients, though the majority had suffered an inferior myocardial infarction, as opposed to our cohort of RV failure following LVAD implantation. 9 Haneya et al. described the use of a minimally invasive surgical RVAD in 8 patients with RV failure following LVAD implantation, and found similar improvement in hemodynamic parameters to those seen in our cohort. 8 These authors described the insertion of the outflow cannula through a Dacron graft anastomosed to the PA meaning that RVAD deployment was more invasive but that removal could be performed with minimal intervention when patients were weaned from RVAD support. Anderson et al.
published the largest study examining the use of percutaneous RV support in a prospective, single-arm trial using the Impella RP. 7 This study included 30 patients with RV failure, 18 of whom required RV support after LVAD implantation. These authors also demonstrated improvement in hemodynamics similar in magnitude to those in our cohort. This study did not have a comparator group but instead compared outcomes to a benchmark established for a contemporary sRVAD. Most recently, Ravichandran et
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A N U S C R I P T al. described the use of the Protek Duo catheter to provide pRVAD support following LVAD implantation. 11 However, our data represent the largest comparison of hemodynamic changes and outcomes between the two device support strategies.
In our cohort of early RV failure patients, support with pRVAD was associated with less morbidity compared with sRVAD support. Specifically, those supported with pRVAD had a shorter period of mechanical ventilation, as well as less requirement for blood transfusion. There was a trend towards improved discharge free from dialysis among the pRVAD group. Additionally, hospital and ICU length of stay after RVAD insertion among survivors was shorter with the percutaneous devices. This decreased morbidity is likely related to multiple factors. First, the pRVAD approach is less invasive, allowing for more rapid recovery from both the implantation and the removal procedure.
Second, though not significant, the median time to pRVAD implantation following LVAD was one third the time to sRVAD placement. In addition, serum creatinine, transaminases, and lactate were numerically lower at baseline (though not statistically significant) in patients receiving pRVAD. Though the difference in time to RVAD implantation was not significantly different, these findings raise the possibility that the ability to rapidly deploy the pRVAD in the cardiac catheterization laboratory may lower the threshold for initiating RV support and, in turn, result in overall improved outcomes.
Planned RVAD support for patients at high risk of RV failure likely remains the optimal strategy when implanting a durable LVAD. 12 Similarly, even when RVAD implantation is unplanned, patients with overt RV failure manifesting in the operating room are likely better supported by concomitant RVAD implantation as opposed to delayed implantation if the patient's condition does not improve. 13 However, the fact that
most of the patients in this cohort were not deemed high risk for RV failure underscores the limitations of the currently available risk models and highlights the need for a rapidly deployed RV support device. Therefore, for RV failure manifesting unexpectedly after LVAD implantation, our data suggest that percutaneous support may be a viable alternative to a surgical support device in many cases.
Limitations
It is important to note that this is a single center, retrospective study, which introduces several important limitations. Because patients were not randomized to sRVAD or pRVAD, there may have been selection bias in their use; furthermore, as both pRVAD systems used are relatively novel, the two cohorts are not entirely contemporary and device use changed over time. It is possible that the risk of RV failure varied with growing experience managing LVAD patients and this may have contributed to differences between the cohorts of patients receiving the different types of RVAD.
Importantly though, we did not note differences in demographic or baseline hemodynamic characteristics between those receiving sRVAD and pRVAD. While we limited our analysis to patients who received continuous-flow LVADs, the risk of RV failure may vary with different pump technology. Additionally, because hemodynamic data were collected retrospectively, full hemodynamic profiles were not available for all patients. The relatively small number of patients in our study limited our ability to detect differences in outcomes between the devices studied, though to our knowledge this is the largest comparison of these two device strategies. Finally, in order to better understand the differences between these two devices, we limited our analysis to
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patients with RV failure after LVAD implantation, thus limiting our ability to extrapolate these conclusions to other etiologies of RV failure.
Conclusion
Novel percutaneous RVAD support systems allow for rapid deployment of RV mechanical support following durable LVAD implantation. These systems provide almost immediate improvement in hemodynamics and are associated with less morbidity than their surgical counterparts, and should be considered viable alternatives to sRVAD placement for this patient population.
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A N U S C R I P T Device Parameters
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